Brokerage Firm Rating Update on Agenus (AGEN)

Agenus (AGEN) : The consensus on Agenus (AGEN) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Agenus (AGEN) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $10 and the lowest price target forecast is $7. The average forecast of all the analysts is $8 and the expected standard deviation is $1.73.


For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Jefferies maintains its rating on Agenus (NASDAQ:AGEN). As per the latest information, the brokerage house raises the price target to $7 per share from a prior target of $6. The shares have been rated Buy. The rating by the firm was issued on July 29, 2016.

Agenus (NASDAQ:AGEN): stock was range-bound between the intraday low of $6.215 and the intraday high of $6.46 after having opened at $6.4 on Wednesdays session. The stock finally closed in the red at $6.4, a loss of -0.79%. The stock remained in the red for the whole trading day. The total traded volume was 1,008,856 shares. The stock failed to cross $6.46 in Wednesdays trading. The stocks closing price on Thursday was $6.32.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.